Hepatocellular Carcinoma

This year’s The Liver Meeting provided many exciting updates for viral hepatitis care ranging from steps toward eliminating hepatitis C to improving hepatitis B treatment options through data on hepatitis D.

BOSTON — Improvements in frailty among patients with cirrhosis awaiting liver transplantation lowered the risk for mortality regardless of baseline frailty and MELD-Na score, according to data presented at The Liver Meeting 2019.

BOSTON — In this exclusive video from The Liver Meeting 2019, Naga P. Chalasani, MD, from the Indiana University School of Medicine, discusses the accuracy of combined methylated DNA and protein markers for early-stage detection of hepatocellular carcinoma.

BOSTON — Triple combination therapy with lonafarnib, ritonavir, and Lambda for chronic hepatitis D appeared safe and tolerable for up to 6 months in most patients and led to high rates of RNA decline, according to data presented at The Liver Meeting 2019.

The FDA granted the combination of nivolumab and ipilimumab priority review and breakthrough therapy designation for the treatment of patients with advanced hepatocellular carcinoma previously treated with sorafenib, according to a company-issued press release.

BOSTON — Researchers found that health care financial burden was common in patients with cirrhosis and may be associated with lower receipt of hepatocellular carcinoma surveillance, according to a presenter at The Liver Meeting 2019.

Albumin levels and liver stiffness measurements taken during direct-acting antiviral therapy follow-up can stratify liver cancer risk among patients with hepatitis C and compensated advanced chronic liver disease, according to study results.

Can-Fite BioPharma announced the initiation of a compassionate use program for Namodenoson to treat patients with hepatocellular carcinoma, according to a press release.

Combination treatment with Tecentriq and Avastin for unresectable hepatocellular carcinoma in patients without prior systemic therapy demonstrated clinically meaningful improvements in both overall and progression-free survival compared with Nexavar, according to a press release from Genentech.

SAN ANTONIO — The National Liver Congress will convene October 25th, providing a broad scientific program and exhibit of products and services important for all practitioners involved in the care of patients with liver disease.